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Abstract
Recent efforts to combat infections have focused on pharmaceutical interventions. However, the global spread of antimicrobial resis-
tance calls for the reappraisal of personal and institutional hygiene. Hygiene embodies behavioural and procedural rules that prevent
bacterial transmission. Consequently, the chance of spreading bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) is signif-
icantly reduced. Hygiene is part of the primacy and totality of patient care, ensuring that no harm is done. Any prevention and control
strategy must be underpinned by changes in attitude, embraced by all. The major components of preventing and controlling MRSA
include hand and environmental hygiene (as part of standard precautions), patient isolation, and patient/staff decolonization. Improving
hand hygiene practice is especially important where the risk of infection is highest, e.g. in intensive care. Physical isolation has two
advantages: the physical barrier interrupts transmission, and this barrier emphasizes that precautions are required. With limited isolation
facilities, risk assessment should be conducted to indicate which patients should be isolated. Environmental hygiene, although important,
has a lower priority than standard precautions. When a patient is ready for discharge (home) or transfer (to another healthcare facility),
the overall interests of the patient should take priority. All patients should be informed of their MRSA-positive status as soon as possi-
ble. Because of increased mupirocin resistance, a selective approach to decolonization should be taken. When MRSA-positive staff are
identiﬁed, restricting their professional activity will depend on the nature of their work. Finally, politicians and others need to commit
to providing the necessary resources to maximize MRSA prevention and control.
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Introduction
In addressing the challenge to modern societies imposed by
infections, too much attention has been focused for the past
half-century on the elimination of the disease-causing patho-
gen, e.g. Staphylococcus aureus, and too little on the factors
involved in transmission leading to infection in a new host,
despite the explanatory power of the germ theory and
Koch’s postulates, recently re-evaluated, in understanding
the aetiology and epidemiology of infections [1]. This empha-
sis on treatment has led to an over-reliance on antimicrobial
chemotherapy, with the consequent emergence of antimicro-
bial resistance.
In the face of increasing resistance and new threats such
as community-acquired methicillin-resistant S. aureus (CA-
MRSA) [2,3], there is a need to re-emphasize the role of
personal and institutional hygiene and of well-known meth-
ods for preventing bacterial transmission within an individual,
among family and household members, within the commu-
nity, and within hospitals and other institutions. Contributory
factors, such as underlying disease or recent major surgery,
are important because they serve to highlight the patients
who are at particular risk.
What follows is a consensus statement derived from
practitioners in the ﬁeld with considerable experience
in the prevention and control of healthcare-associated
infection (HCAI), including MRSA.
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Underlying Principles of Prevention and
Control
When drafting recommendations for preventing and control-
ling infection, in acute-care hospitals or elsewhere, important
principles govern the primacy and totality of patient care.
These ensure that well-intended infection prevention and
control measures do not compromise other important
aspects of patient care. They include:
1 Ensurance that infection prevention and control measures
do not harm the patient.
2 Adherence to high standards of professionalism, including
basic personal hygiene on the part of all healthcare work-
ers (HCWs).
3 Agreement on professional dress codes.
4 Compliance with a minimum standard of hospital cleanli-
ness, i.e. visible cleanliness (absence of dirt and soilage)
that is acceptable to patients, staff and visitors [4].
Measures to minimize and prevent MRSA must not be adopted
at the expense of other aspects of patient care, as patients
with infections due to MRSA have the same rights to the
highest standards of care as all other patients. This means that
the necessary resources, both physical and with respect to
personnel, to care for patients with MRSA must be provided.
Patient-to-patient contact, primarily via the hands of
HCWs, is thought to be the primary route of transmission
of MRSA. Contact transmission includes direct and indirect
contact. Preventive strategies are therefore directed at inter-
rupting the chain of transmission. MRSA carriers repeatedly
contaminate their hands by touching colonized body parts,
e.g. the nose, especially in cases of unknown asymptomatic
carriage, and the capacity of S. aureus to survive for months
in a dry, often relatively hostile, environment contributes to
environmental reservoirs of MRSA, e.g. door handles and
beds. The principles behind the prevention and control of
HCAI have been known for some time, and are incorporated
into many national MRSA guidelines [5], but it has repeatedly
proven difﬁcult to apply them. Therefore, although there are
speciﬁc interventions that are recognized as being important,
e.g. hand hygiene, any strategy that includes a number of spe-
ciﬁc interventions must be supported by major changes in
attitude. This behavioural change must be embraced by all
concerned in the organization, i.e. healthcare executives as
well as the HCWs delivering services.
The prevention and control of MRSA and all HCAIs
must be a priority of government agencies and healthcare
executives with responsibility for the delivery of healthcare.
Good professional practice, e.g. hand hygiene and the use of
protective clothing, must be undertaken by all HCWs, and
they in turn must be empowered to change practice where
this is suboptimal. Leadership is necessary to drive this
change and to ensure the implementation of good practices.
Continuous education is a key component in achieving this.
It is important to re-emphasize the importance of hygiene in
hospitals and all healthcare premises. With advances in many
areas of healthcare and the widespread use of antibiotics for
50 years and more, the importance of personal hygiene, on the
part of both patients and healthcare professionals, as well as of
environmental hygiene is increasingly less recognized. High
standards of hygiene are important not just for acute healthcare
facilities, including outpatient clinics, but also for long-term-care
facilities such as nursing homes, and for home-based care.
Prevention and Control Measures
Hand hygiene
Hands are the vehicles for a plethora of functions in daily
clinical care, including:
1 Interaction with the inanimate physical environment, e.g.
opening doors.
2 Personal interaction, e.g. shaking hands, and comforting
patients or relatives.
3 Diagnostic procedures, e.g. palpation and percussion.
4 Administration of food and medicines.
5 Placement and manipulation of indwelling (percutaneous)
devices, e.g. catheters.
6 Washing, cleaning, etc.
There are many customs, habits, beliefs and attitudes that
result in different behaviours, and that inﬂuence our knowl-
edge about the role of hands in medical care and our under-
standing of hands as the most important vectors for the
transmission of pathogens. There are also many reasons why
compliance with hand hygiene recommendations differs lar-
gely among cultures, professional groups, social strata, and
genders [6]. There is also a need to fully embrace and adopt
international guidelines such as the WHO ﬁrst global patient
safety challenge [7] and to provide support as needed for full
implementation of the guidelines.
We believe that hand hygiene is a global standard of
care for patients in all healthcare settings, in both resource-
adequate and resource-constrained environments. This has
clear beneﬁts for all, not least the reduction in the possibili-
ties of the international transfer of MRSA.
Priorities for improving compliance with hand hygiene
include areas where the risk of infection is highest, e.g. spe-
cialist care units such as intensive-care units and burn units.
CMI Humphreys et al. Consensus statement on the prevention and control of MRSA 121
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 120–124
Success in these settings will serve as an example for
improving practice in other clinical areas.
Hand hygiene, an integral component of standard precau-
tions (SPs), underpins infection prevention and control in all
clinical areas. Leadership is required to ensure that all health-
care workers are familiar with the components of SPs and
that compliance is maximized. Quality indicators for the
assessment of everyday processes should be agreed upon, on
the basis of national and local standards, and audited on a
regular basis.
Isolation/cohorting
The physical isolation of a patient with infection due to
MRSA, either in a single room or as part of a cohort unit, has
two advantages: (i) the physical barrier between an MRSA-
positive patient and other patients helps to interrupt trans-
mission; and (ii) the psychological message that this barrier
gives to HCWs by highlighting the necessary precautions.
Ideally, all MRSA patients should be isolated, but this may not
be possible, depending upon the prevalence of MRSA locally
and nationally. For example, in units where MRSA represents
less than 5% of all S. aureus isolates, there may be sufﬁcient
single rooms available, but in countries where over 25% of
S. aureus isolates are methicillin-resistant, the requirement of
single rooms for other reasons may preclude this, as may the
sheer absolute numbers of MRSA patients needing isolation.
Recent mathematical modelling strongly suggests that in both
endemic and epidemic settings of MRSA, it is possible to
signiﬁcantly reduce MRSA rates, and that this is cost-effective
even when the cost of the enhanced diagnostic and control
measures is taken into account [8].
Where there is limited isolation capacity, risk assessment
should be conducted to determine which patients should be
isolated, based upon the likelihood of transmission. Patients
with, for example, underlying skin diseases such as eczema,
who are more likely to shed large numbers of MRSA organ-
isms, must be given priority. Other considerations include
the possible impact of MRSA spread to vulnerable patients,
e.g. orthopaedic patients, who are particularly vulnerable to
chronic debilitating infections due to MRSA. Where a patient
with MRSA is isolated or cohorted, it is preferable to have
separate HCWs, especially nursing staff, caring for the
patient in isolation, in order to minimize transmission.
Environmental decontamination
The environment has been documented as being a source of
MRSA or as being involved in transmission, but it is not clear
how important this is relative to other factors [9], e.g. subopti-
mal compliance with hand hygiene. A clean environment is par-
ticularly important in the case of surfaces that are frequently
touched, e.g. monitors and keyboards, by which HCWs may
transmit MRSA to patients via their hands. Although environ-
mental hygiene has a lower priority in prevention and control
than do SPs and hand hygiene, cleanliness and general environ-
mental hygiene are important, and failure in this sphere may
demotivate HCWs and detract from patient care.
Ofﬁcial documents pertaining to building standards (at the
national, regional and local levels) should embrace hygiene as
a priority. Recommendations for optimal facilities, e.g. the
physical and environmental parameters outlined in the guide-
lines concerning intensive-care unit design issued by the
European Society of Intensive Care Medicine [10], should be
adopted, especially when units are being built, upgraded, or
refurbished. Furthermore, each ward or clinical area should
be capable of isolating/cohorting MRSA-colonized or MRSA-
infected patients. Moving patients from one ward to another
for isolation/cohorting may compromise overall care for the
patients by depriving them of specialized care or facilities.
Also, unnecessary patient movement facilitates the spread of
MRSA within an institution.
The intensity of measures necessary to achieve environ-
mental decontamination depends on the circumstances, the
level of environmental contamination, and the risk to
patients, and perhaps a standard requiring more than merely
visual cleanliness may have a greater impact on MRSA trans-
mission [11]. In many circumstances, warm water and simple
detergent, when applied appropriately, are adequate to signif-
icantly reduce the burden of MRSA in the environment. The
additional use of disinfectants contributes to efforts to eradi-
cate MRSA, but the use of disinfectants must be governed by
risk and circumstances.
Patient discharges/transfers
When a patient is ready for discharge (home) or transfer
(another hospital or healthcare facility), the overall interests
of the patient should take priority. The discharge (home) of
MRSA-infected patients, when clinically appropriate, will
reduce the risk of transmission to other patients that might
occur in the hospital.
All patients (and/or their relatives, as appropriate) should
be informed as soon as possible of their MRSA-positive sta-
tus. In addition, those institutions to which a patient is being
transferred, e.g. another hospital or a long-term-care facility,
must be informed of a patient’s MRSA-positive status.
Patients and their relatives should also be educated about
the signiﬁcance of MRSA, its possible consequences for the
particular patient, its mode of transmission, and how to
reduce the risk of transmission.
Because MRSA colonization may be prolonged, i.e. over
12 months, it is important to include all partners concerned
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with the delivery of healthcare (i.e. hospitals, long-term-care
facilities (public and private nursing homes), general practitio-
ners, tissue viability clinics etc.) in a coordinated approach.
The importance of district (regional) infection control teams
harmonizing approaches and addressing the respective needs
of the institutions serving the same catchment population
should therefore be emphasized. For example, agreement
may be possible on minimizing the inter-institution transfer
of patients with MRSA, to reduce the possibilities of trans-
mission, while safeguarding the right of the individual patient
to whatever care he or she requires. Transparency and clear
communication processes are critical once patients with
MRSA have been discharged or transferred to another insti-
tution. The inclusion of general practitioners is essential, as
they can advise on personal hygiene (e.g. the exchange or
sharing of fomites such as towels and clothing), including
sports-related and sexual hygiene, which is potentially impor-
tant in true CA-MRSA transmission.
MRSA Decolonization of Patients and HCWs
Patients
The literature available on the effectiveness of eradication of
MRSA, which depends on the setting and the number of
patients studied, is often somewhat confusing [12]. The expe-
rience from Denmark and from other countries with low
MRSA prevalence rates shows that decolonization can be suc-
cessful in the long term, especially when a holistic approach,
including the treatment of the patient’s family, is taken. This
must also be accompanied by environmental cleaning. There is
an urgent need for randomized studies in settings with differ-
ent prevalence rates of MRSA, to determine whether decolo-
nization truly diminishes the transmission of MRSA, and if so,
where and when. There is also a need for the development
of, and trials in, alternative regimens for decolonization.
Because of the increasing emergence of mupirocin resis-
tance, especially after repeated courses of mupirocin treat-
ment [13] when MRSA-colonized patients are identiﬁed, a
selective approach to decolonization with mupirocin, taking
risk factors into consideration, should be taken, rather than
the automatic use of this agent for all patients. Patients due
for surgery, particularly surgery involving an implantable
device such as an artiﬁcial hip, should be decolonized before
surgery; the same holds for liver and stem cell transplant
recipients, who are at risk of poor outcome from invasive
MRSA infection. Other patients, for whom the risk of infec-
tion is lower and the consequences are less severe, should
be decolonized according to a risk assessment. However, all
MRSA-positive patients can undergo chlorhexidine baths.
There are several principles that should inﬂuence when
patient decolonization is attempted:
1 Decolonization should not be attempted as long as there
is active MRSA infection.
2 Patients with foreign bodies (devices) or patients with
underlying skin conditions, which will reduce the possibil-
ity of successful decolonization, should preferably await
the removal of the foreign body (device) or the treat-
ment of the skin condition before MRSA decolonization
regimens are started.
3 Topical treatments (e.g. with mupirocin for nasal car-
riage) should be used ﬁrst, before recourse to the use of
systemic antibiotics.
4 The decolonization of patients with CA-MRSA must be
accompanied by environmental cleaning [3], and consider-
ation should be given to decolonizing other MRSA-posi-
tive members of a household.
HCWs
There are differences among countries in the approach to the
screening of HCWs for MRSA, which may be followed by decol-
onization and, in some cases, re-location to work with a lower
risk of transmission. In low-endemicity countries such as The
Netherlands and Denmark, this is an important component of
eradication. In countries where MRSA is endemic, HCW screen-
ing is less frequently used. Therefore, due consideration needs
to be given to the role that staff screening may play, depending
on the local prevalence, and the impact that the identiﬁcation of
MRSA-positive HCWs may have on control. Staff identiﬁed
as MRSA-positive should be offered decolonization, with, for
example, chlorhexidine baths or mupirocin treatment, to pre-
vent MRSA transmission to patients and their relatives. Where
necessary, assistance should be sought from dermatologists,
occupational health workers, and other professional groups.
Restriction of the professional activity of MRSA-positive
staff will be dependent on the general situation in the institu-
tion and upon the nature of their work. Greater restrictions
will apply in clinical areas where the consequences of MRSA
acquisition are greatest for patients, e.g. in intensive-care units.
Unaddressed Issues
1 All prevention and control measures are dependent upon
the early identiﬁcation of MRSA-positive patients,
whether colonized or infected. Therefore, screening poli-
cies and the choice of the sites optimal for screening play
a key role in the identiﬁcation of MRSA-positive patients
and in the application of control measures [14].
CMI Humphreys et al. Consensus statement on the prevention and control of MRSA 123
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 120–124
2 The appropriate and sensible use of antibiotics, i.e. antibi-
otic stewardship, is of importance if the chances of MRSA
emergence and spread are to be reduced. Antibiotic stew-
ardship has been comprehensively addressed elsewhere,
e.g. by study groups of the European Society of Clinical
Microbiology and Infectious Diseases [15], and the scientiﬁc
basis for the use of antibiotics (which may or may not be
appropriate), which contributes to the emergence and spr-
ead of MRSA, has been exhaustively reviewed recently [16].
Conclusions
Success in preventing and controlling MRSA is dependent on
the appropriate attitude and high standards of professionalism
among all who deliver healthcare, as well as on strong leader-
ship and appropriate governance to highlight the importance
of all HCAIs and MRSA infections. Standard precautions, espe-
cially hand hygiene, together with isolation/cohorting, educa-
tion and patient decolonization in selected circumstances, are
key components of MRSA prevention and control measures.
Every reasonable measure should be taken to maximize
efforts to prevent and control MRSA, but HCWs are reminded
of the maxim ‘ﬁrst do no harm’. The overall welfare and safety
of the patient is of paramount importance, and measures under-
taken to control MRSA should not compromise the safety and
quality of patient care. Therefore, politicians, administrators and
national bodies need to commit to providing the necessary
human resources (e.g. nursing staff and appropriate experts)
and physical resources (e.g. adequate numbers of isolation
rooms) to optimize efforts to prevent and control MRSA.
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